Exact Sciences (EXAS) Q3 Revenues Beat
Tweet
Share
E-mail
Get Alerts EXAS Hot Sheet
Price: $104.91 --0%
Financial Fact:
Total Operating expenses: 54.23M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Total Operating expenses: 54.23M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($1.46), which may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $408.4 million versus the consensus estimate of $337.37 million. COVID-19 testing revenue was $102.2 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- GameStop beats second quarter estimates on collectibles
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
